The usefulness of anamorelin for iPPFE
- Conditions
- idiopathic pleuroparenchymal fibroelastosis
- Registration Number
- JPRN-jRCTs041220165
- Lead Sponsor
- Yasui Hideki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Patients over 20 years old
Patients diagnosed with iPPFE based on CT imaging and clinical findings
Patients whose consent for this study has been obtained by signing a consent form
Patients with a history of hypersensitivity to anamorelin
Patients with congestive heart failure
Patients with myocardial infarction or angina pectoris
Patients with severe conduction defects (e.g., complete atrioventricular block)
Patients who have received or are currently taking the following drugs within 1 week prior to the start of study treatment: clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir-containing products, cobicistat-containing products
Patients with hepatic dysfunction of moderate severity or greater (Child-Pugh classification B and C)
Patients with difficulty in oral intake of food due to obstruction of the gastrointestinal tract or other organic abnormality of the gastrointestinal tract
Patients with diabetes mellitus who have poor glycemic control despite the use of oral diabetes medications or insulin
Pregnant or nursing mothers
Patients who are deemed inappropriate by the principal investigator (or sub-investigator)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method